Edwards Lifesciences Stated Maturities decreased by 20.9% to $44.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 39.5%, from $73.10M to $44.20M.
A concentration of maturities in the near term increases liquidity risk, while a balanced profile suggests better long-term stability.
This refers to the contractual dates upon which financial instruments, such as debt or loans, are scheduled to mature. I...
Standard disclosure for all financial institutions to demonstrate asset-liability management.
stated_maturities| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $255.10M | $353.60M | $490.40M | $454.50M | $472.30M | $331.20M | $292.90M | $247.70M | $158.00M | $119.30M | $95.80M | $73.10M | $64.00M | $55.90M | $44.20M |
| QoQ Change | — | +38.6% | +38.7% | -7.3% | +3.9% | -29.9% | -11.6% | -15.4% | -36.2% | -24.5% | -19.7% | -23.7% | -12.4% | -12.7% | -20.9% |
| YoY Change | — | — | — | +78.2% | +33.6% | -32.5% | -35.6% | -47.6% | -52.3% | -59.3% | -61.3% | -53.7% | -46.4% | -41.6% | -39.5% |